Tag
A recent randomized clinical trial reveals that adjunctive intravenous ketamine significantly reduces depressive symptoms in treatment-resistant bipolar depression, with good safety and tolerability compared to midazolam.
A propensity score analysis of STEP-BD data reveals no significant association between antidepressant use and either manic switch risk or symptomatic remission in bipolar depression, highlighting the need for alternative treatment strategie
The PAX-BD trial assessed pramipexole addition to mood stabilisers in treatment-resistant bipolar depression, revealing some mood and psychosocial benefits but no significant primary outcome improvement, highlighting the need for further re
